In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation ...

On 11 February 2025, the Commission unveiled its 2025 work program, titled “Moving forward together: A Bolder, Simpler, Faster Union.” This annual document sets out upcoming legislative and policy ...

As U.S. antitrust counsel to global companies, it is increasingly important to track major developments in the international ...

On the subject of the Grail acquisition, deSouza remains defiant, despite recent decisions by antitrust authorities in the US and Europe ordering Illumina to roll back the merger – which are ...

Cambridge life science cluster’s most exciting companies, has gone through a huge overhaul in the boardroom – including a ...

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego ...

Let’s get out of here. I don’t want to see anybody.” Those were the words of polymath thinker, actor, entertainer and ...